Code : 9345-351880      Created Date : Wednesday, October 5, 2016   Visit : 1569

RCPsych International Congress 2016

The report of RCPsych International Congress 2016 by Dr. Shahin Akhondzadeh
Application Code :
306-0216-0079
 
Created Date : Saturday, July 23, 2016-18:40 18:40:45Update Date : Sunday, July 31, 2016-14:38 14:38:11
IP Address : 194.225.51.101Submit Date : Sunday, July 31, 2016-14:40 14:40:55Email : s.akhond@neda.net
Personal Information
Name : Shahin
Surname : Akhondzadeh
School/Research center : School of Medicine
If you choose other, please name your Research center :  
Position : Professor
Tel : +98-21-66418466
Information of Congress
Title of the Congress : RCPsych International Congress 2016
Title of your Abstract : Efficacy and safty of oral ketamine versus Diclifenac to alleviate Mild to moderate depression in chronic pain patients: A double blind, randomised, clinical trial
Destination Country : United Kingdom
From : Monday, June 27, 2016
To : Thursday, June 30, 2016
Abstract(Please copy/paste the abstract send to the congress) : Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist capable of exerting antidepressive effects in single or repeated intravenous infusions. The objective of this study was to investigate the safety and the efficacy of oral ketamine vs. diclofenac monotherapy in reducing symptoms of mild to moderate depression among patients with chronic pain. This study is a 6-week, randomized, double-blind, controlled, parallel-group trial with two intervention arms (ketamine, fixed daily dosage of 150 mg vs. diclofenac, fixed daily dosage of 150 mg). Twenty participants in each arm completed the trial program all of whom had two post-baseline measurements at week 3 and week 6. Reduction in depression symptoms was assessed using the Hamilton Depression Rating Scale (HDRS) and the hospital anxiety and depression subscale for depression (HADS Depression) scores at baseline and week 3 and week 6 post-intervention. Significantly lower HDRS scores were observed in the ketamine treatment group as early as 6 weeks post-intervention (P = 0.008). By comparison, mean (± standard deviation) HADS depression subscale scores were significantly lower for individuals receiving ketamine compared to diclofenac for both post-baseline measures at week 3 (6.95 ± 1.47 vs. 8.40 ± 1.6, P = 0.005) and week 6 (6.20 ± 1.15 vs. 7.35 ± 1.18, p = 0.003). No serious adverse event was reported in any of the patients. Oral ketamine appears to be a safe and effective option in improving depressive symptoms of patients with chronic pain with mild-to-moderate depression.
Keywords of your Abstract : Oral Ketamine; Diclofenac; Depression; Randomized Controlled Trial
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/15395/Forms/306/invitation10001.pdf
The presentation : eposter
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/15395/Forms/306/poster10001.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/15395/Forms/306/poster10001_1.pdf
Where has your abstract been indexed? : none
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : 6000 scientists from several counties
Delegates from which countries presented in the congress? : more thAN 50 COUNTRIES INCLUDING usa, gERMANY, fRANCE
Were the delegates of any other organizations present in the congress? : No
If yes, please write the names of the organizations in the box :  
What were the responses to your talking points? Were specific questions or concerns raised? : Our study was very intersting for other scientsists and they have lots of questions like this one:
You have received the below message from an attendee via your iPoster.
To reply, click on the sender's email address to send them an email directly. Do not use Reply or Reply all.

Name: have you a pdf copy you ould email me please?
Email: ANGUS.BELL@NHS.NET

GREAT WORK! We have an iv ketamine climic for TRD here in Teessid UK. Knd regards, Dr Angus Bell

 
If you met staff members, please list their full names & positions. : tHE PRESIDENT OF CONGRESS
Please inform us if there are any follow up actions we need to talk with the members of the congress : At the present nothing but I keep communication with the scientists in particular regarding joint progects on ketamine use in patients with chronic pain and mild to moderate depression in particular the patients in general hospitals such as neurology or surgery wards. Since the current medications for depression is not very ideal, the ketamine anidepressants effects can open a new window for treatment of depression
Your experiences about the travel processes(Providing ticket, accommodation,...) : IT WAS FINE
Please give a briefing of your own observations and outcomes of the congress: : It was a very organized meetinf with top international level and I was the only person fron Iran. Nevertheless, you could feel the security atmosphere in London. My main concern is step by step the number of Iranian scientists that can attend in International congress is decreasing (except the congress that supported by pharmaceutical company) and instead of that in this congress about 100 scientist attended fron Sudi Arabia and Emirate and we should think about that. 15 years ago it was visa versa

 

Your Comments :
captcha
Close